PhRMA: Proposed rebates would weaken Part D

A bill was unveiled by Democrats this week in Congress to require rebates from drugmakers on prescription treatments used by beneficiaries of both Medicare Part D and Medicaid. Drugmakers say the plan would weaken Part D and amounts to "mandatory government price controls ... cleverly disguised as 'rebates.'" The measure "would bring higher premiums and co-pays, more restricted access to medicines for seniors and Americans with disabilities, and diminished research on the next generation of medicines," PhRMA Senior Vice President Matthew Bennett said.

View Full Article in:

PharmaTimes (U.K.) · Pharma Letter (U.K.) (subscription required), The · AARP.org